Navigation Links
Press statement on new CDC MMWR on Klebseilla pneumonia Carbapenemase-producing organisms
Date:3/18/2009

The Centers for Disease Control and Prevention (CDC) today released new infection control recommendations on Klebseilla pneumoniae Carbapenemase (KPC)-Producing Organisms, one of the most treatment-resistant gram-negative bacterium. Recent studies have shown that infections with these highly resistant bacteria are a growing problem in health care settings. In Guidance for Control of Infections with Carbapenem-Resistant or Carbapenemase-Producing Enterobacteriaceae in Acute Care Facilities published in the MMWR, CDC recommends an aggressive infection control approach to limit the emergence of these organisms.

Below Are Quotes from Mark Rupp, MD, President of SHEA

"The new guidelines highlight the need to educate clinicians and public health professionals about the importance of screening for Klebsiella pneuomoniae Carbapenemase (KPC)-Producing Organisms. If hospitals follow the CDC guidelines to detect and identify Klebsiella and Carbapenemase, then we can potentially halt the transmission of a highly treatment-resistant Gram-negative organism and prevent a large scale public health problem.

While KPC is still rare and occurs only sporadically in most parts of the country, an aggressive infection control approach needs to be taken now. These new guidelines suggest that facilities start by checking microbioloigy results for the last six to twelve months. Facilities finding evidence of these organisms should conduct a focused risk assessment or examine high-risk wards including intensive care units to make sure there is no evidence of ongoing transmission. The strategy for testing uses a selection process to get rid of most other organisms and focuses on the ones that are likely to be treatment-resistant including Carbapenem resistant Klebsiella.

For example, Israel has had widespread public health problems with these organisms, yet has managed to contai
'/>"/>

Contact: Sharon Reis
sreis@gymr.com
202-745-5103
Society for Healthcare Epidemiology of America
Source:Eurekalert

Page: 1 2

Related biology news :

1. Regulatory molecule for tumor formation or suppression identified by Singapore, US researchers
2. American Chemical Societys weekly PressPac -- March 11, 2009
3. New tracking tags are providing fish-eye views of ways to manage depressed fisheries
4. Is it really only our kidneys that control blood pressure?
5. Researchers take first look at the genetic dynamics of inbreeding depression
6. Study suggests salt might be natures antidepressant
7. Children seriously affected when a parent suffers from depression
8. Chantix side effects no worse with depression history
9. Suppressing cancer with a master control gene
10. Press statement on new CDC MRSA study from SHEA president
11. Molecule that suppresses immune response under study in type 1 diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/9/2015)... , July 9, 2015  Unchained Labs just ... its acquisition of Avid Nano. Avid Nano designs, ... (DLS) systems.    Also today, Unchained ... and easiest to use protein sizing system. The ... a protein,s hydrodynamic size, size distribution, aggregation population ...
(Date:7/8/2015)... YORK , July 8, 2015 Summary ... globally, and the fourth most fatal, with a mortality ... The poor prognosis of pancreatic cancer patients has highlighted ... treatment, which is not being met by the current ... an array of products with varying molecule types and ...
(Date:7/8/2015)... July 8, 2015  Trovagene, Inc. (NASDAQ: ... today announced the launch of a study that ... Cancer Monitoring℠ (PCM) technology for predicting response to ... a combination of the novel immunotherapy agents Yervoy® ... PD-1 inhibitor. The 50-patient study will be led ...
Breaking Biology News(10 mins):Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4
... funding of a world-leading suite of software that allows scientists ... total 1.43M of funding has been awarded to eight components ... application process. Seven of the eight projects are ... funding the eighth. CCP4, which has contributors from ...
... have shown natural radioactivity within DNA can alter chemical ... The research, recently published in Biochimica et Biophysica ... natural radioactivity within human DNA on the atomic-scale. ... well as in every living organism across the planet, ...
... Espoo, Finland and Ebersberg, Germany, December 17th, 2013 - ... line of Eurofins Scientific and Orion Diagnostica Oy, an ... and sales of diagnostic test systems, announced that they ... Oy owns the global rights for the SIBA isothermal ...
Cached Biology News:Radioactivity muddles the alphabet of DNA 2
(Date:7/30/2015)... ... July 31, 2015 , ... Ralco is honored to announce that ... County Fair to be held August 5-9 in Marshall. The Ralco Enrichment Center is ... from and how agriculture impacts their daily lives. This unique exhibit also features a ...
(Date:7/30/2015)... According to a new market ... PB/PK, PKPD, Trial Design, Toxicity Prediction, In-house, Contract Service), ... by End Users - Global Forecast to 2020", published ... USD 2,107.99 million by 2020 from USD 1,034.93 million ... Browse more than 75 ...
(Date:7/30/2015)... , July 30, 2015 Ascendis Pharma ... that applies its innovative TransCon technology to address ... results from a six-month Phase 2 study to ... Growth Hormone in 53 treatment-naïve, pre-pubertal children with ... are extremely pleased with the top-line results from ...
(Date:7/29/2015)... , July 30, 2015 ... results for the second quarter of 2015. CEO ... results and its performance in different businesses. ... http://www.eurobusinessmedia.com/ceo-direct/sanofi/sanofi-h1-2015-results-interview-with-ceo-olivier-brandicourt?utm_source=ceo-direct&utm_medium=wire Topics covered ... results - Performance drivers ...
Breaking Biology Technology:Ralco Announces Primary Sponsorship of Ralco Enrichment Center at Lyon County Fair 2Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7
... ... in prison for murder; guilty man kills again. , ... Rochester, NY (PRWEB) May 5, 2010 -- National Association of ... criminal investigations. A recent WHEC.com story concerns what can only be described as ...
... 4, 2010) Endoscopic radiofrequency ablation is an effective ... a fast and effective way to detect inflammatory bowel ... gastrointestinal tissue that is removed, and researchers find that ... bile duct) is more precise than surgery with fewer ...
... 4 InterMune, Inc. (Nasdaq: ITMN ) today announced that ... for the New Drug Application (NDA) for Esbriet™ (pirfenidone) for the treatment ... function. , , , ... letter is issued by the FDA,s Center for Drug Evaluation and Research ...
Cached Biology Technology:NACVSA Points out Perils of Polygraph: Killer Passes Polygraph, Innocent Man Fails, Killer Goes On To Kill Again 2NACVSA Points out Perils of Polygraph: Killer Passes Polygraph, Innocent Man Fails, Killer Goes On To Kill Again 3NACVSA Points out Perils of Polygraph: Killer Passes Polygraph, Innocent Man Fails, Killer Goes On To Kill Again 4Latest breakthroughs in technology expand options for diagnosing and treating disease 2Latest breakthroughs in technology expand options for diagnosing and treating disease 3Latest breakthroughs in technology expand options for diagnosing and treating disease 4Latest breakthroughs in technology expand options for diagnosing and treating disease 5Latest breakthroughs in technology expand options for diagnosing and treating disease 6Latest breakthroughs in technology expand options for diagnosing and treating disease 7Latest breakthroughs in technology expand options for diagnosing and treating disease 8Latest breakthroughs in technology expand options for diagnosing and treating disease 9Latest breakthroughs in technology expand options for diagnosing and treating disease 10Latest breakthroughs in technology expand options for diagnosing and treating disease 11InterMune Receives FDA Complete Response Letter on Esbriet(TM) (Pirfenidone) New Drug Application 2InterMune Receives FDA Complete Response Letter on Esbriet(TM) (Pirfenidone) New Drug Application 3InterMune Receives FDA Complete Response Letter on Esbriet(TM) (Pirfenidone) New Drug Application 4InterMune Receives FDA Complete Response Letter on Esbriet(TM) (Pirfenidone) New Drug Application 5
... Oligo Spots and complementary RNA Spikes for ... Use for glass array printing and for ... transcription, cDNA labeling, hybridization stringency and background. ... PCR Spots and Oligo Spots, and complementary ...
MOUSE ANTI DUCK IgY LIGHT CHAIN...
MOUSE ANTI S. MUTANS PEPTIDOGLYCAN...
ANTI END CEL LUNG AG...
Biology Products: